A randomized, double-blinded, placebocontrolled phase 2 study of the ERC-1671 (Gliovac) vaccine in combination with bevacizumab (BEV) in recurrent GBM patients: Safety lead-in analysis

Authors
Category Primary study
JournalNeuro-Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 1f88ded07d71a7ffe20bdd49b9ac6b191f3cdc75
First added on: Feb 08, 2025